Bottom line
FBT vs RYOIX: the short answer
FBT (First Trust NYSE Arca Biotechnology Index Fund) and RYOIX (Biotechnology Fund) are quite different portfolios: only about 30% of their top holdings (by weight) are shared.
But RYOIX is far broader, holding 74 positions to 32 for FBT, so beyond the top names it adds exposure FBT doesn't have.
FBT is cheaper at 0.55% vs 1.38% — a difference of $83 a year per $10,000 invested.
Over five years, FBT returned +4.3% a year vs +4.0% for RYOIX.
Updated Nov 19, 2026
FBT vs RYOIX side by side
| FBT | RYOIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | First Trust | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.55% | 1.38% |
| Annual cost per $10k | $55 | $138 |
| 10-yr cost on $10k (prospectus) | — | $1,709 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +24.1% | +30.7% |
| 5-yr return (annualized) | +4.3% | +4.0% |
| 10-yr return (annualized) | +6.3% | +5.9% |
| Best quarter | +27.8% | +28.3% |
| Worst quarter | −22.5% | −22.5% |
| Net assets (fund) | $2.8B | $136.8M |
| Number of holdings | 32 | 74 |
| Portfolio turnover | 37% | 75% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBT | RYOIX | Difference |
|---|---|---|---|
| 2025 | +24.1% | +30.7% | −6.6% |
| 2024 | +5.8% | −0.7% | +6.5% |
| 2023 | +2.3% | +6.1% | −3.8% |
| 2022 | −4.6% | −13.1% | +8.5% |
| 2021 | −3.6% | +1.8% | −5.4% |
| 2020 | +12.9% | +22.1% | −9.2% |
| 2019 | +19.8% | +25.0% | −5.2% |
| 2018 | −0.2% | −9.0% | +8.8% |
| 2017 | +37.0% | +29.7% | +7.3% |
| 2016 | −19.6% | −19.5% | −0.1% |
Source: Fund prospectus bar charts
Holdings overlap
10 of FBT's top 25 holdings also appear in RYOIX's top 25.
| Holding | FBT | RYOIX |
|---|---|---|
| Illumina Inc | 3.92% | 1.94% |
| Natera Inc | 3.79% | 2.12% |
| Neurocrine Biosciences Inc | 3.53% | 1.52% |
| Biogen Inc | 3.37% | 2.13% |
| Incyte Corp | 3.18% | 1.62% |
| Argenx Se | 3.13% | 1.48% |
| Vertex Pharmaceuticals Inc | 3.07% | 4.32% |
| Amgen Inc | 2.78% | 5.05% |
| United Therapeutics Corp | 2.56% | 1.72% |
| Alnylam Pharmaceuticals Inc | 2.52% | 2.36% |
Source: SEC Form N-PORT
FBT top 10
- Corcept Therapeutics Inc — 5.60%
- Neogenomics Inc — 5.12%
- Veracyte Inc — 5.10%
- Bruker Corp — 4.32%
- Alkermes Plc — 4.24%
- Illumina Inc — 3.92%
- Krystal Biotech Inc — 3.87%
- Natera Inc — 3.79%
- Axsome Therapeutics Inc — 3.71%
- Neurocrine Biosciences Inc — 3.53%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between FBT and RYOIX?
Which is cheaper, FBT or RYOIX?
Should I own both FBT and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.